Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Activation of Oncogenic Super-Enhancers Is Coupled with DNA Repair by RAD51.

Hazan I, Monin J, Bouwman BAM, Crosetto N, Aqeilan RI.

Cell Rep. 2019 Oct 15;29(3):560-572.e4. doi: 10.1016/j.celrep.2019.09.001.

2.

AntimiR-155 Cyclic Peptide-PNA Conjugate: Synthesis, Cellular Uptake, and Biological Activity.

Soudah T, Khawaled S, Aqeilan RI, Yavin E.

ACS Omega. 2019 Aug 12;4(9):13954-13961. doi: 10.1021/acsomega.9b01697. eCollection 2019 Aug 27.

3.

Editorial: WW Domain Proteins in Signaling, Cancer Growth, Neural Diseases, and Metabolic Disorders.

Chang NS, Lin R, Sze CI, Aqeilan RI.

Front Oncol. 2019 Aug 2;9:719. doi: 10.3389/fonc.2019.00719. eCollection 2019. No abstract available.

4.

Correction: Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation.

Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian JB.

J Biol Chem. 2019 Jun 21;294(25):10018. doi: 10.1074/jbc.AAC119.009552. No abstract available.

5.

Correction: Negative Regulation of the Hippo Pathway by E3 Ubiquitin Ligase ITCH Is Sufficient to Promote Tumorigenicity.

Salah Z, Melino G, Aqeilan RI.

Cancer Res. 2019 Jun 1;79(11):3007. doi: 10.1158/0008-5472.CAN-19-1086. No abstract available.

PMID:
31160310
6.

Decoding the link between WWOX and p53 in aggressive breast cancer.

Abdeen SK, Aqeilan RI.

Cell Cycle. 2019 Jun;18(11):1177-1186. doi: 10.1080/15384101.2019.1616998. Epub 2019 May 16.

PMID:
31075076
7.

MiR-16-1-3p and miR-16-2-3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma.

Maximov VV, Akkawi R, Khawaled S, Salah Z, Jaber L, Barhoum A, Or O, Galasso M, Kurek KC, Yavin E, Aqeilan RI.

Int J Cancer. 2019 Dec 1;145(11):3052-3063. doi: 10.1002/ijc.32368. Epub 2019 May 9.

PMID:
31018244
8.

Fhit-Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells.

Druck T, Cheung DG, Park D, Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, Okumura H, Iuliano R, Raso C, Green K, Huebner K, Croce CM.

Cell Death Dis. 2019 Feb 15;10(3):147. doi: 10.1038/s41419-019-1414-7.

9.

WWOX somatic ablation in skeletal muscles alters glucose metabolism.

Abu-Remaileh M, Abu-Remaileh M, Akkawi R, Knani I, Udi S, Pacold ME, Tam J, Aqeilan RI.

Mol Metab. 2019 Apr;22:132-140. doi: 10.1016/j.molmet.2019.01.010. Epub 2019 Jan 31.

10.

WWOX Inhibits Metastasis of Triple-Negative Breast Cancer Cells via Modulation of miRNAs.

Khawaled S, Suh SS, Abdeen SK, Monin J, Distefano R, Nigita G, Croce CM, Aqeilan RI.

Cancer Res. 2019 Apr 15;79(8):1784-1798. doi: 10.1158/0008-5472.CAN-18-0614. Epub 2019 Jan 8.

PMID:
30622118
11.

Author Correction: WWOX controls hepatic HIF1α to suppress hepatocyte proliferation and neoplasia.

Abu-Remaileh M, Khalaileh A, Pikarsky E, Aqeilan RI.

Cell Death Dis. 2018 Nov 23;9(12):1159. doi: 10.1038/s41419-018-1158-9.

12.

Modeling WWOX Loss of Function in vivo: What Have We Learned?

Tanna M, Aqeilan RI.

Front Oncol. 2018 Oct 10;8:420. doi: 10.3389/fonc.2018.00420. eCollection 2018. Review.

13.

Somatic loss of WWOX is associated with TP53 perturbation in basal-like breast cancer.

Abdeen SK, Ben-David U, Shweiki A, Maly B, Aqeilan RI.

Cell Death Dis. 2018 Aug 6;9(8):832. doi: 10.1038/s41419-018-0896-z.

14.

Microenvironmental Cues Determine Tumor Cell Susceptibility to Neutrophil Cytotoxicity.

Gershkovitz M, Fainsod-Levi T, Khawaled S, Shaul ME, Sionov RV, Cohen-Daniel L, Aqeilan RI, Shaul YD, Fridlender ZG, Granot Z.

Cancer Res. 2018 Sep 1;78(17):5050-5059. doi: 10.1158/0008-5472.CAN-18-0540. Epub 2018 Jul 2.

15.

MicroRNA-214 promotes hepatic stellate cell activation and liver fibrosis by suppressing Sufu expression.

Ma L, Yang X, Wei R, Ye T, Zhou JK, Wen M, Men R, Li P, Dong B, Liu L, Fu X, Xu H, Aqeilan RI, Wei YQ, Yang L, Peng Y.

Cell Death Dis. 2018 Jun 18;9(7):718. doi: 10.1038/s41419-018-0752-1.

16.

WWOX controls hepatic HIF1α to suppress hepatocyte proliferation and neoplasia.

Abu-Remaileh M, Khalaileh A, Pikarsky E, Aqeilan RI.

Cell Death Dis. 2018 May 1;9(5):511. doi: 10.1038/s41419-018-0510-4. Erratum in: Cell Death Dis. 2018 Nov 23;9(12):1159.

17.

TRPM2 Mediates Neutrophil Killing of Disseminated Tumor Cells.

Gershkovitz M, Caspi Y, Fainsod-Levi T, Katz B, Michaeli J, Khawaled S, Lev S, Polyansky L, Shaul ME, Sionov RV, Cohen-Daniel L, Aqeilan RI, Shaul YD, Mori Y, Karni R, Fridlender ZG, Binshtok AM, Granot Z.

Cancer Res. 2018 May 15;78(10):2680-2690. doi: 10.1158/0008-5472.CAN-17-3614. Epub 2018 Feb 28.

18.

TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line.

Gaudio E, Paduano F, Pinton S, D'Agostino S, Rocca R, Costa G, Ngankeu A, Aqeilan RI, Croce CM, Bertoni F, Alcaro S, Trapasso F.

Br J Haematol. 2018 Nov;183(3):509-512. doi: 10.1111/bjh.14989. Epub 2017 Oct 19. No abstract available.

PMID:
29048125
19.

Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells.

Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, Okumura H, Iuliano R, Di Leva G, Fabbri M, Birk DE, Raso C, Green-Church K, Spagnoli LG, Venuta S, Huebner K, Croce CM.

J Biol Chem. 2017 Aug 25;292(34):14279. doi: 10.1074/jbc.A117.709062. No abstract available.

20.

RUNX1, a new regulator of EMT in breast cancer.

Khawaled S, Aqeilan RI.

Oncotarget. 2017 Mar 14;8(11):17407-17408. doi: 10.18632/oncotarget.15623. No abstract available.

21.

Tumor Suppressor Genes within Common Fragile Sites Are Active Players in the DNA Damage Response.

Hazan I, Hofmann TG, Aqeilan RI.

PLoS Genet. 2016 Dec 15;12(12):e1006436. doi: 10.1371/journal.pgen.1006436. eCollection 2016 Dec. Review.

22.

WWOX and p53 Dysregulation Synergize to Drive the Development of Osteosarcoma.

Del Mare S, Husanie H, Iancu O, Abu-Odeh M, Evangelou K, Lovat F, Volinia S, Gordon J, Amir G, Stein J, Stein GS, Croce CM, Gorgoulis V, Lian JB, Aqeilan RI.

Cancer Res. 2016 Oct 15;76(20):6107-6117. Epub 2016 Aug 22.

23.

Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development.

Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM.

Cancer Cell. 2016 Aug 8;30(2):349-351. doi: 10.1016/j.ccell.2016.07.007. Epub 2016 Aug 8. No abstract available.

24.

WWOX guards genome stability by activating ATM.

Hazan I, Abu-Odeh M, Hofmann TG, Aqeilan RI.

Mol Cell Oncol. 2015 Feb 23;2(4):e1008288. doi: 10.1080/23723556.2015.1008288. eCollection 2015 Oct-Dec.

25.

A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells.

Gaudio E, Paduano F, Ngankeu A, Ortuso F, Lovat F, Pinton S, D'Agostino S, Zanesi N, Aqeilan RI, Campiglia P, Novellino E, Alcaro S, Croce CM, Trapasso F.

Oncotarget. 2016 May 24;7(21):29927-36. doi: 10.18632/oncotarget.9179.

26.

Genetic factors conferring metastasis in osteosarcoma.

Maximov VV, Aqeilan RI.

Future Oncol. 2016 Jul;12(13):1623-44. doi: 10.2217/fon-2016-0014. Epub 2016 Apr 13.

PMID:
27072870
27.

WWOX modulates the ATR-mediated DNA damage checkpoint response.

Abu-Odeh M, Hereema NA, Aqeilan RI.

Oncotarget. 2016 Jan 26;7(4):4344-55. doi: 10.18632/oncotarget.6571.

28.

Pleiotropic Functions of Tumor Suppressor WWOX in Normal and Cancer Cells.

Abu-Remaileh M, Joy-Dodson E, Schueler-Furman O, Aqeilan RI.

J Biol Chem. 2015 Dec 25;290(52):30728-35. doi: 10.1074/jbc.R115.676346. Epub 2015 Oct 23. Review.

29.

Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function.

Del Mare S, Aqeilan RI.

Sci Rep. 2015 Aug 10;5:12959. doi: 10.1038/srep12959.

30.

WWOX loss activates aerobic glycolysis.

Abu-Remaileh M, Seewaldt VL, Aqeilan RI.

Mol Cell Oncol. 2014 Oct 30;2(2):e965640. doi: 10.4161/23723548.2014.965640. eCollection 2015 Apr-Jun.

31.

miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells.

Salah Z, Arafeh R, Maximov V, Galasso M, Khawaled S, Abou-Sharieha S, Volinia S, Jones KB, Croce CM, Aqeilan RI.

Oncotarget. 2015 Mar 10;6(7):4920-35.

32.

T538 phosphorylation, Pin-ing p63-Itch stability.

Alian A, Aqeilan RI.

Cell Cycle. 2015;14(4):469-70. doi: 10.1080/15384101.2015.1006553. No abstract available.

33.

Current questions and controversies in chromosome fragile site research: does WWOX, the gene product of common fragile site FRA16D, have a passive or active role in cancer?

Hazan I, Aqeilan RI.

Cell Death Discov. 2015 Oct 19;1:15040. doi: 10.1038/cddiscovery.2015.40. eCollection 2015. No abstract available.

34.

The tumor suppressor WW domain-containing oxidoreductase modulates cell metabolism.

Abu-Remaileh M, Aqeilan RI.

Exp Biol Med (Maywood). 2015 Mar;240(3):345-50. doi: 10.1177/1535370214561956. Epub 2014 Dec 8. Review.

35.
36.

FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs.

Suh SS, Yoo JY, Cui R, Kaur B, Huebner K, Lee TK, Aqeilan RI, Croce CM.

PLoS Genet. 2014 Oct 23;10(10):e1004652. doi: 10.1371/journal.pgen.1004652. eCollection 2014 Oct.

37.

WWOX, the common fragile site FRA16D gene product, regulates ATM activation and the DNA damage response.

Abu-Odeh M, Salah Z, Herbel C, Hofmann TG, Aqeilan RI.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4716-25. doi: 10.1073/pnas.1409252111. Epub 2014 Oct 20.

38.

Epigenetic pathways regulating bone homeostasis: potential targeting for intervention of skeletal disorders.

Gordon JA, Montecino MA, Aqeilan RI, Stein JL, Stein GS, Lian JB.

Curr Osteoporos Rep. 2014 Dec;12(4):496-506. doi: 10.1007/s11914-014-0240-1. Review.

39.

The common fragile site FRA16D gene product WWOX: roles in tumor suppression and genomic stability.

Aqeilan RI, Abu-Remaileh M, Abu-Odeh M.

Cell Mol Life Sci. 2014 Dec;71(23):4589-99. doi: 10.1007/s00018-014-1724-y. Epub 2014 Sep 23. Review.

PMID:
25245215
40.

Role of common fragile sites and corresponding genes in cancer development.

Aqeilan RI.

Cell Mol Life Sci. 2014 Dec;71(23):4487-8. doi: 10.1007/s00018-014-1716-y. Epub 2014 Sep 20. Review. No abstract available.

PMID:
25238781
41.

Tumor suppressor WWOX regulates glucose metabolism via HIF1α modulation.

Abu-Remaileh M, Aqeilan RI.

Cell Death Differ. 2014 Nov;21(11):1805-14. doi: 10.1038/cdd.2014.95. Epub 2014 Jul 11.

42.

The WWOX gene modulates high-density lipoprotein and lipid metabolism.

Iatan I, Choi HY, Ruel I, Reddy MV, Kil H, Lee J, Odeh MA, Salah Z, Abu-Remaileh M, Weissglas-Volkov D, Nikkola E, Civelek M, Awan Z, Croce CM, Aqeilan RI, Pajukanta P, Aldaz CM, Genest J.

Circ Cardiovasc Genet. 2014 Aug;7(4):491-504. doi: 10.1161/CIRCGENETICS.113.000248. Epub 2014 May 28.

43.

Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks.

Abu-Odeh M, Bar-Mag T, Huang H, Kim T, Salah Z, Abdeen SK, Sudol M, Reichmann D, Sidhu S, Kim PM, Aqeilan RI.

J Biol Chem. 2014 Mar 28;289(13):8865-80. doi: 10.1074/jbc.M113.506790. Epub 2014 Feb 18.

44.

WW domain-containing oxidoreductase's role in myriad cancers: clinical significance and future implications.

Gardenswartz A, Aqeilan RI.

Exp Biol Med (Maywood). 2014 Mar;239(3):253-63. doi: 10.1177/1535370213519213. Epub 2014 Feb 7. Review.

PMID:
24510053
45.

Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel.

Gaudio E, Paduano F, Spizzo R, Ngankeu A, Zanesi N, Gaspari M, Ortuso F, Lovat F, Rock J, Hill GA, Kaou M, Cuda G, Aqeilan RI, Alcaro S, Croce CM, Trapasso F.

PLoS One. 2013 Nov 6;8(11):e78610. doi: 10.1371/journal.pone.0078610. eCollection 2013.

46.

NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation.

Salah Z, Cohen S, Itzhaki E, Aqeilan RI.

Cell Cycle. 2013 Dec 15;12(24):3817-23. doi: 10.4161/cc.26672. Epub 2013 Oct 7. Erratum in: Cell Cycle. 2019 May;18(9):1045.

47.

Hippo signaling: to die or not to die.

Aqeilan RI.

Cell Death Differ. 2013 Oct;20(10):1287-8. doi: 10.1038/cdd.2013.100. No abstract available.

48.

Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapy.

Salah Z, Bar-mag T, Kohn Y, Pichiorri F, Palumbo T, Melino G, Aqeilan RI.

Cell Death Dis. 2013 Jan 31;4:e480. doi: 10.1038/cddis.2013.6.

49.

Characterization of WWOX inactivation in murine mammary gland development.

Abdeen SK, Salah Z, Khawaled S, Aqeilan RI.

J Cell Physiol. 2013 Jul;228(7):1391-6. doi: 10.1002/jcp.24310.

PMID:
23254778
50.

Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype.

Abdeen SK, Del Mare S, Hussain S, Abu-Remaileh M, Salah Z, Hagan J, Rawahneh M, Pu XA, Russell S, Stein JL, Stein GS, Lian JB, Aqeilan RI.

J Cell Physiol. 2013 Jul;228(7):1377-82. doi: 10.1002/jcp.24308.

Supplemental Content

Loading ...
Support Center